Table 2. Clinical and Molecular Characteristics of IDH-Mutated ET Patients.

UPN	Age	G	IDH	JAK2 (allele burden)	FU	OS	Drug	Survival
1	55	M	IDH1 R132C	(-)	64	64	Hydroxyurea, ASA	Alive
2	33	F	IDH2 R140Q	(+) (5%)	52	60	Hydroxyurea	Alive

UPN indicates unique patient number. G: gender; F: female; M: male; FU: follow-up (months); OS: overall survival (months).